ImmuPharma secures £50m to develop ex-Cephalon asset
This article was originally published in Scrip
Executive Summary
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor.
You may also be interested in...
ImmuPharma Puts On Very Brave Face After Lupus Drug Flop
Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.